Skip to main content
CRL
NYSE Industrial Applications And Services

Charles River Labs Lifts 2026 Outlook on Q2 Beat as DSA Book-to-Bill Reaches Four-Year Peak

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$253
Mkt Cap
$11.277B
52W Low
$144.26
52W High
$242.73
52W Position info
75% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CRL sits 75% above its 52-week low of $144.26.

Summary

Charles River Laboratories posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, raised its full-year guidance, and highlighted the highest DSA book-to-bill in nearly four years, signaling a strengthening demand recovery.

Updates

  1. · SEC 10-Q — Net loss of $1.5 million includes $63.7 million divestiture charge; CEO adopted 10b5-1 plan.

  2. · dpa-AFX — GAAP EPS guidance was cut to $3.05-$3.35 due to divestiture losses, and shares rose 8.8% pre-market to $254.73.

  3. · Reuters — Revenue hit $1 billion vs. $975.7 million consensus; adjusted EPS of $3.02 beat $2.74 estimate. Stock is near a 52-week high.


Key Events · Earnings and Guidance · CRL

  • Q2 Revenue and EPS Beat

    Driven by improving demand in DSA and better Manufacturing performance, revenue reached $1.00 billion (organic growth +0.1%) and non-GAAP EPS came in at $3.02, exceeding the prior outlook.

  • Full-Year Guidance Raised

    Reflecting operational outperformance, 2026 organic revenue growth guidance was raised to 0.0%–1.0% (from -1.5% to -0.5%) and non-GAAP EPS to $11.15–$11.45 (from $10.80–$11.30).

  • DSA Book-to-Bill Hits 4-Year High

    The Discovery and Safety Assessment segment recorded its highest net book-to-bill in nearly four years, indicating strengthening future revenue from both large pharma and biotech clients.

  • $100M Buyback at $174/Share

    In Q2, 0.6 million shares were repurchased for $100 million at an average price of $174, well below the current $253, with $700 million remaining on the $1 billion authorization.


Analysis · CRL · Industrial Applications And Services

The strongest organic revenue growth since Q3 2023 and a raised full-year outlook signal that the demand recovery in Charles River's core DSA segment is gaining real traction. A net book-to-bill ratio at its highest in nearly four years points to building future revenue, while the $100 million buyback executed at an average price of $174—well below today's $253—adds a capital-return tailwind. The GAAP loss stems entirely from one-time divestiture charges, not operational weakness; non-GAAP EPS of $3.02 beat expectations and drove the guidance raise. With the stock trading near its 52-week high, the market has already priced in some optimism, but improving demand trends and the raised outlook provide fundamental support.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRL was trading at $253.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $144.26 to $242.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRL - Latest Insights

CRL
Nov 09, 2026, 6:10 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $337.44
Real-time Price: $345.80 info
Change: +$8.36 (+2%) info
Market Cap: $16.57B info
CRL
Nov 04, 2026, 9:03 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $342.99
Real-time Price: $345.80 info
Change: +$2.81 (+0.82%) info
Market Cap: $16.57B info
CRL
Nov 04, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $362.01
Real-time Price: $345.80 info
Change: -$16.21 (-4%) info
Market Cap: $16.57B info
CRL
Nov 04, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $362.00
Real-time Price: $345.80 info
Change: -$16.20 (-4%) info
Market Cap: $16.57B info
CRL
Sep 24, 2026, 8:12 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $278.01
Real-time Price: $345.80 info
Change: +$67.79 (+24%) info
Market Cap: $16.57B info